$微創機器人-B(02252.HK)$ Finally on, but did not hit a new subscription. The market is not friendly to unprofitable start-ups, and expect a more comfortable price. Kingsley bio and minimally invasive robotics are the most focused directions for innovative drugs and innovative medical devices in the future. It is nothing more than the time and rhythm of the completion of the warehouse.
$微創機器人-B(02252.HK)$ The big Four are 10 years ahead of their time in technology, waiting for the world to catch up, and they have their own medical robots. Da Vinci launched its products in 2000 based on the underlying technology of the robot industry. The more cases there are, the more powerful they are.
$微創機器人-B(02252.HK)$Personal View of minimally invasive robot Several key points, not profitable, High ling IPO increase, JPMORGAN Chase sponsor, expected 50% callback, IPO for the previous investment rise range is still ok, speculation new mood has not recovered; In summary, in terms of playing new, the probability of winning is almost 50/50, the odds are not high, if the call back to break the resistance to save slightly bigger
$微創機器人-B(02252.HK)$Make money on short-term market sentiment. Since we are only new, we need to have a clear positioning, just to make money in the dark market or the first two days of the listing. So, listed the first time is up or down for us is the most important! Even if you think that the future of this new stock must be bright, the future must be a big bull, and we hit the new is not related to, because we can not wait for the distant future.
微創機器人-B股票討論區
K線組合有望走出雙底形態,技術指標KDJ已經金叉發散,預計短線股價仍有上行空間
專欄不段说:meta/fb都簽了他們?!元宇宙概念還有調整買入機會嗎?
4:25 unity业绩被错待,为什么元宇宙重要股有它?u.us 、mttr.us $Unity Software(U.US)$ $Matterport(MTTR.US)$ $Meta Platforms(FB.US)$ $英偉達(NVDA.US)$
19:46 元宇宙投资周期到底有多长?
22:00 为什么说疫苗相关股的逻辑被破坏掉了?腾盛(2137) $騰盛博藥-B(02137.HK)$ 开拓药业(9939) $開拓藥業-B(09939.HK)$ $輝瑞(PFE.US)$
29:43 QA 保利协鑫(3800) $協鑫科技(03800.HK)$ 、片仔癀(600436) $片仔癀(600436.SH)$
Finally on, but did not hit a new subscription. The market is not friendly to unprofitable start-ups, and expect a more comfortable price. Kingsley bio and minimally invasive robotics are the most focused directions for innovative drugs and innovative medical devices in the future. It is nothing more than the time and rhythm of the completion of the warehouse.
The big Four are 10 years ahead of their time in technology, waiting for the world to catch up, and they have their own medical robots. Da Vinci launched its products in 2000 based on the underlying technology of the robot industry. The more cases there are, the more powerful they are.
Several key points, not profitable, High ling IPO increase, JPMORGAN Chase sponsor, expected 50% callback, IPO for the previous investment rise range is still ok, speculation new mood has not recovered;
In summary, in terms of playing new, the probability of winning is almost 50/50, the odds are not high, if the call back to break the resistance to save slightly bigger
暫無評論